News

Tower Mains Weekly Newsletter Regulatory Updates EMA and HMA confirm biosimilar medicines can be interchanged On 19th September, the EMA and the Heads of Medicines Agencies (HMA) issued a joint [...]

Tower Mains Weekly Newsletter Industry Updates EMA approves adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 On 12th September, the European Medicines Agency (EMA) announced its human [...]

Tower Mains Weekly Newsletter Industry Updates First adapted COVID-19 booster vaccines recommended for approval in the EU  On 1st September, the European Medicines Agency (EMA) announced its human medicines committee [...]

Tower Mains Weekly Newsletter Company Updates Check out our latest ‘Meet the Team’ blog post on our Head of Clinical & Quality Management, Marina Freiberga. Marina tells us what initially [...]

Tower Mains Weekly Newsletter Company News Risk Management in your Quality Management System (QMS) – is it effective? In their first Linkedin live short webinar series our QMS team discusses: [...]

Tower Mains Weekly Newsletter Company Updates We have been published in the August issue of QUASAR, the Research Quality Association (RQA)'s renowned membership magazine. Check out our article on how [...]

Tower Mains Weekly Newsletter Company Updates We have exciting news! Tower Mains is delighted to announce the following promotions:   Our Associate Director and Head of Operations Lianne Roeling will be [...]

Tower Mains Weekly Newsletter Regulatory Updates International Council on Harmonisation (ICH) M10 Guideline Issued On 27th July, final ICH M10 guideline on Bioanalytical Method Validation and Study Sample Analysis has [...]